A recent investigation has shed light on the origins of psychotic symptoms that manifest later in life, specifically after the age of 40. This groundbreaking study suggests that these symptoms, such as hallucinations and delusions, are frequently rooted in underlying neurodegenerative pathologies. By employing advanced molecular positron emission tomography (PET) imaging, researchers discovered a significant prevalence of abnormal tau protein accumulation in approximately 65% of patients experiencing late-onset psychosis. Furthermore, 35% of these patients exhibited amyloid-beta positivity. These findings represent a crucial step forward, offering direct in vivo evidence that midlife psychiatric manifestations can be directly linked to distinct neurodegenerative pathways within the living human brain.
Traditionally, psychiatric symptoms appearing for the first time in middle age or later have been categorized as psychiatric disorders with unclear biological underpinnings. Standard psychiatric evaluations primarily rely on self-reported symptoms, often failing to detect underlying neurodegenerative processes, such as the accumulation of tau and amyloid proteins. This oversight can lead to varied responses to treatment. The study, published in Molecular Psychiatry, indicates that for many individuals, these symptoms might be connected to brain alterations also observed in dementia. Manabu Kubota, the lead researcher, highlighted that despite similar symptoms like hallucinations or delusions, patients' clinical trajectories and responses to treatment can differ significantly. This research aimed to explore whether hidden biological variations in the brain could account for these discrepancies.
To investigate the biological markers of the disease, the research team analyzed 37 patients who developed psychosis after age 40, comparing them with 47 healthy older adults. They utilized amyloid PET and QST’s specialized tau PET tracer, florzolotau (18F), which is capable of visualizing a wide array of tau pathologies in the living brain. The PET scans revealed a higher incidence of tau positivity among the patients, along with diverse patterns of tau accumulation. Some patients displayed amyloid-positive patterns consistent with Alzheimer's disease, while others exhibited amyloid-negative patterns, suggesting distinct non-Alzheimer's disease types of tau-related neurodegeneration. In patients who were amyloid-negative, tau accumulation was particularly concentrated in the posterior brain regions, specifically the parietal and occipital lobes, areas vital for visual processing, attention, and higher-order spatial cognition.
The study also established a link between tau buildup and cognitive function. Among amyloid-positive patients, increased tau accumulation in the parietal lobe was associated with reduced executive function, encompassing abilities like planning and attentional control. This suggests that the quantity of tau in the brain could help elucidate certain clinical characteristics observed in late-onset psychosis. The diagnosis and treatment of Alzheimer’s disease are increasingly reliant on the detection of amyloid and tau in the brain. However, objective biological tools for diagnosing hallucinations and delusions have remained scarce. These new discoveries may facilitate earlier diagnosis and intervention for late-onset psychosis, based on quantifiable brain changes rather than solely on symptoms.
Looking ahead, researchers anticipate that PET-based assessments could enable more tailored treatments. By identifying whether a patient's symptoms are related to Alzheimer's-type or non-Alzheimer's-type tau pathology, future therapies could be selected or developed to target the patient’s specific underlying disease process. This personalized approach holds promise for improving outcomes for individuals grappling with late-onset psychotic disorders.